MARK BAPTISTE: Open Payments
NPI 1396271938 · CAMDEN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$802 in 47 payments from 8 companies in 2025. Trend: 2023 $99 · 2024 $410 · 2025 $802
Food & beverage: $802
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $212 |
| ABBVIE INC. | 9 | $141 |
| Neurocrine BioSciences, Inc. | 6 | $124 |
| Otsuka America Pharmaceutical, Inc. | 5 | $83 |
| Vanda Pharmaceuticals Inc. | 4 | $73 |
| E.R. Squibb & Sons, L.L.C. | 4 | $65 |
| Janssen Pharmaceuticals, Inc | 3 | $54 |
| Lundbeck LLC | 3 | $51 |
Products named: AUSTEDO XR, VRAYLAR, INGREZZA, REXULTI, FANAPT, COBENFY, INVEGA SUSTENNA, UZEDY.
Industry payments across NJ — which companies pay providers there.
